This transgenic mouse overexpresses MYCN through a tyrosine hydroxylase promoter (TH-MYCN) and was the first model used to demonstrate that MYCN amplification can drive neuroblastoma development, highlighting the MYCN pathway as a potential therapeutic target. Here, MYCN is linked to neuroblastoma.